Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on November 20, 2017, 10:40:45 am
-
People who are cured of hepatitis C virus (HCV) when they have minimal or no liver fibrosis (scarring) have a very low rate of liver-health problems during the subsequent three years.
Researchers analyzed data from the Gilead SVR Registry, which includes individuals who entered the registry within three months of being cured of hep C with a regimen including at least one of the direct-acting antiviral medications manufactured by Gilead Sciences. These include Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Epclusa (sofosbuvir/velpatasvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir). The registry members received follow-up testing of liver-health measures every 24 weeks after their cure for up to 144 weeks.
Read more...
https://www.hepmag.com/article/curing-hepatitis-c-early-tied-low-longterm-liver-health-risks